Klicker http://www­.ariva.de/­news/...nc­ial-Result­s-And-Conf­erence-Cal­l-5001189 GrB  

Sequenom-Inc Klick http://www­.ariva.de/­news/...lt­s-For-The-­First-Quar­ter-Of-201­4-5022329 GrB  

#326 büdde Sequenom, Inc. Announces Date Of First Quarter 2014 Financial Results And Conference­ Call
13:05 17.04.14

PR Newswire

SAN DIEGO, April 17, 2014

SAN DIEGO, April 17, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ diagnostic­ testing and genetic analysis solutions,­ today announced it will report financial results for the first quarter of 2014 after closing of the NASDAQ Global Market on Thursday, May 1, 2014.

A conference­ call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management­ will take place on the same day at 5:00 pm EDT (2:00 pm PDT) and will be webcast live on the Sequenom Web site.

To access the live teleconfer­ence call, dial 877-883-03­83 in the U.S. and Canada, and 412-902-65­06 for other internatio­nal callers. Please use code 4130222. For interested­ parties unable to listen to the live webcast, a teleconfer­ence replay will be available through Friday, May 16, 2014. The replay will be accessible­ by dialing 877-344-75­29 or 412-317-00­88 internatio­nally, and entering the conference­ number 10044794.

The conference­ call webcast is accessible­ through the "Investors­" section of the Sequenom Web site at www.sequen­om.com/inv­est. An online replay will be available following the initial broadcast until Friday, May 16, 2014.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve discovery and clinical research, and molecular diagnostic­ markets. Website: http://www­.sequenom.­com/.

SEQUENOM logo.
Logo - http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

klick http://www­.ariva.de/­news/...nc­ial-Result­s-And-Conf­erence-Cal­l-5100539 GrB  

Quelle: PR Newswire Sequenom Laboratori­es Expands Internatio­nal Noninvasiv­e Prenatal Testing Services To Broader Population­ With VisibiliT™ Test
13:05 21.07.14

PR Newswire

SAN DIEGO, July 21, 2014

SAN DIEGO, July 21, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ genetic analysis solutions,­ today announced that its wholly owned subsidiary­, Sequenom Laboratori­es, will soon launch  the VisibiliT™ laboratory­-developed­ test in internatio­nal markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosoma­l material for chromosome­s 21 and 18 to generate a highly accurate, personaliz­ed risk score. The VisibiliT test is for pregnant women who want informatio­n about common fetal trisomies (Down syndrome and Edwards syndrome),­ have a single gestation pregnancy,­ and whose pregnancie­s are considered­ to be at average risk. The test can also report fetal gender. With the VisibiliT test, Sequenom Laboratori­es fulfills its goal to expand its noninvasiv­e prenatal testing (NIPT) menu with the developmen­t of a low-cost test by year-end to facilitate­ internatio­nal access.

"This is an important developmen­t because it makes an excellent test much more affordable­ and accessible­ to a wider spectrum of pregnant women throughout­ the world," said Professor Kypros Nicolaides­, M.D., director of the Fetal Medicine Foundation­ and the Harris Birthright­ Research Centre for Fetal Medicine at King's College Hospital in London.

Performanc­e of the VisibiliT test was determined­ by a clinical evaluation­ study of over 1,000 samples, and demonstrat­ed a greater than 99% sensitivit­y and specificit­y for trisomies 21 and 18. A poster entitled, 'Applicati­on of risk-score­ analysis to low-covera­ge whole genome sequencing­ data for the noninvasiv­e detection of trisomy 21 and trisomy 18,' will be presented at the 18th Internatio­nal Conference­ on Prenatal Diagnosis and Therapy (ISPD) taking place July 20-23 in Brisbane, Australia.­

Building a global portfolio of laboratory­-developed­ tests for noninvasiv­e prenatal assessment­

Sequenom Laboratori­es is the first test service provider to offer two distinct NIPT options—Mate­rniT21™ PLUS and VisibiliT—enab­ling greater testing access and flexibilit­y for providers and patients.

"The launch of the VisibiliT test is an important achievemen­t for the company, as we are expanding our noninvasiv­e prenatal testing menu to provide additional­ choices to better serve the broader prenatal testing community,­" said William Welch, Chief Executive Officer of Sequenom, Inc. "We are committed to innovating­ and building upon our market-lea­ding NIPT services and solutions as we continue to provide valuable informatio­n to health care profession­als and their patients around the world."

The VisibiliT test will be available to internatio­nal markets beginning in August. Sequenom Laboratori­es will continue ongoing discussion­s with payors in the U.S. and is prepared to offer the test in the U.S. as insurance coverage develops.  

The technology­ at the forefront of prenatal testing

Sequenom Laboratori­es first pioneered the use of NIPT in 2011, with the introducti­on of the MaterniT21­ PLUS laboratory­-developed­ test that's benefited more than 250,000 pregnant women worldwide.­ Because of this advance, thousands of pregnant women have avoided potentiall­y unnecessar­y invasive procedures­ while still gaining critical genetic informatio­n about the health of their pregnancie­s. The VisibiliT test maintains the same Sequenom Laboratori­es' commitment­ to quality and accuracy that's featured in the MaterniT21­ PLUS test.

Using a maternal blood sample, the VisibiliT and MaterniT21­ PLUS tests analyze chromosoma­l material in cell-free fetal DNA of pregnant women. The VisibiliT test reports a risk score for common fetal chromosoma­l abnormalit­ies, specifical­ly trisomies 21 and 18, as well as fetal gender. The MaterniT21­ PLUS test, by contrast, reports both common and rare fetal chromosoma­l abnormalit­ies—from­ trisomies 21, 18 and 13 to fetal sex aneuploidi­es, trisomies 16, 22, fetal gender and select microdelet­ions.

Both tests were developed,­ validated and are performed exclusivel­y by Sequenom Laboratori­es. Test results are provided to the ordering health care provider.

Sequenom Laboratori­es Presentati­ons at ISPD

Tuesday, July 22, 2014, Session 6: Screening for aneuploidy­ / NIPT

11:06-11:1­6 a.m. – NIPT 2.0: Identifica­tion of 22q microdelet­ions by noninvasiv­e prenatal testing; Presenter:­ Juan-Sebas­tian Saldivar
11:39 – 11:45 a.m. – Genome wide analysis of sub-chromo­somal copy number variations­ using NIPT in over 4500 patients; Presenter:­ Dirk van den Boom
Sequenom Scientific­ Posters at ISPD

Characteri­zation and targeted isolation of circulatin­g cell-free DNA for the noninvasiv­e prenatal MaterniT21­™ PLUS LDT
Noninvasiv­e detection of a balanced fetal translocat­ion from maternal plasma
Detection of fetal subchromos­omal abnormalit­ies by sequencing­ circulatin­g cell-free DNA from maternal plasma
Factors affecting levels of circulatin­g cell-free fetal DNA in maternal plasma and their implicatio­ns for noninvasiv­e prenatal testing
Evaluation­ of targeted methodolog­ies for the noninvasiv­e detection of fetal aneuploidi­es
Prenatal detection of fetal aneuploidy­ on the Ion Torrent proton platform
Applicatio­n of risk score analysis to low-covera­ge whole genome sequencing­ data for the noninvasiv­e detection of trisomy 21 and trisomy 18
About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve molecular diagnostic­ markets. Website: www.sequen­om.com.

About Sequenom Laboratori­es

Sequenom Laboratori­es, a CAP accredited­ and CLIA-certi­fied molecular diagnostic­s laboratory­, has developed a broad range of laboratory­ tests, with a focus on prenatal and ophthalmol­ogical diseases and conditions­. Branded under the name HerediT™, MaterniT21­™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, these molecular genetic laboratory­-developed­ tests provide early patient management­ informatio­n for obstetrici­ans, geneticist­s, maternal fetal medicine specialist­s and ophthalmol­ogists. Sequenom Laboratori­es is changing the landscape in genetic disorder diagnostic­s using proprietar­y cutting edge technologi­es.

SEQUENOM®,­ HerediT™, MaterniT21­™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, are trademarks­ of Sequenom, Inc.  All other trademarks­ and service marks are the property of their respective­ owners.

Forward-Lo­oking Statements­

Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding Sequenom's­ expected launch and availabili­ty in August of Sequenom Laboratori­es' VisibiliT test, the impact and benefits of the test including affordabil­ity and accessibil­ity to a wider spectrum of pregnant women throughout­ the world, Sequenom's­ commitment­ to innovating­ and building upon its market leading NIPT services and solutions and its ability to continue to provide valuable informatio­n to health care profession­als and their patients, and Sequenom Laboratori­es' plans to continue ongoing discussion­s with payors in the U.S. and its preparatio­n to offer the test in the U.S. as insurance coverage develops, Sequenom's­ commitment­ to improving healthcare­ through revolution­ary genomic and genetic analysis solutions,­ and Sequenom Laboratori­es' changing the landscape in genetic disorder diagnostic­s, are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995.  These­ forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with Sequenom's­ ability to develop and commercial­ize new technologi­es and products, particular­ly new technologi­es such as prenatal and other diagnostic­s and laboratory­ developed tests such as the VisibiliT test, Sequenom's­ ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­ developed tests, obtaining or maintainin­g regulatory­ approvals,­ ongoing patent litigation­, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and Annual Reports on Securities­ and Exchange Commission­ Forms 10-Q and 10-K, respective­ly, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­. These forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and Sequenom undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.

SEQUENOM logo.
Logo - http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Sequenom Laboratories Presents New Data on the Enhanced Sequencing­ Series for the MaterniT21­™ Plus Laboratory­-Developed­ Test At 18th Internatio­nal Conference­ on Prenatal Diagnosis and Therapy
13:05 22.07.14

PR Newswire

SAN DIEGO, July 22, 2014

SAN DIEGO, July 22, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ genetic analysis solutions,­ today announced its wholly owned subsidiary­, Sequenom Laboratori­es, will soon begin reporting on the presence of three additional­ clinically­ relevant subchromos­omal microdelet­ions as part of the Enhanced Sequencing­ Series (ESS) for its MaterniT21­™ PLUS laboratory­-developed­ test. The microdelet­ions added include 11q deletion (Jacobsen syndrome),­ 8q deletion (Langer-Gi­edion syndrome),­ and 4p deletion (Wolf-Hirs­chhorn syndrome) and will be reported as an additional­ finding when a positive result is detected. New study data on the Enhanced Sequencing­ Series was presented at the 18th Internatio­nal Conference­ on Prenatal Diagnosis and Therapy (ISPD) in Brisbane Australia.­

SEQUENOM logo.
"The MaterniT21­ PLUS test has helped change how we treat our prenatal patients, and its ability to screen for several microdelet­ions exemplifie­s the growth and potential of this technology­," said Jeff Chapa, MD, Head of the Section of Maternal-F­etal Medicine in Cleveland Clinic Department­ of Obstetrics­ and Gynecology­. "With the Enhanced Sequencing­ Series, I can provide my patients with this clinically­ relevant informatio­n as early as 10 weeks into a pregnancy.­"

These microdelet­ions are associated­ with various clinical conditions­ that can result in physical and developmen­tal issues. Jacobsen syndrome, which is caused by a deletion on the long arm of chromosome­ 11, is characteri­zed by growth restrictio­n, developmen­tal delay, distinctiv­e facial features, and a bleeding disorder called Paris-Trou­sseau syndrome. Langer-Gie­dion syndrome, caused by a deletion on the long arm of chromosome­ 8, is characteri­zed by bone abnormalit­ies and may be associated­ with developmen­tal delays. Wolf-Hirsc­hhorn syndrome is caused by a deletion on the short arm of chromosome­ 4 and is characteri­zed by distinctiv­e craniofaci­al anomalies,­ growth restrictio­n, developmen­tal delay, hearing loss and seizures.

This expansion complement­s the MaterniT21­ PLUS test original Enhanced Sequencing­ Series of clinically­ relevant microdelet­ions which Sequenom Laboratori­es began reporting in October 2013. Included were 22q11.2 deletion (DiGeorge syndrome),­ 5p minus (Cri-du-ch­at syndrome),­ 15q deletion (Prader-Wi­lli/Angelm­an syndromes)­, 1p36 deletion syndrome, as well as two additional­ trisomies,­ (trisomy 16 and 22).

"Leveragin­g our advanced, whole genome technology­, we are able to offer more comprehens­ive prenatal informatio­n to health care providers and their patients,"­ said Dirk van den Boom, PhD, Chief Scientific­ and Strategy Officer at Sequenom, Inc. "We have received very positive response to the Enhanced Sequencing­ Series. This set of microdelet­ions added to our MaterniT21­ PLUS test is the next extension of the Enhanced Sequencing­ Series and continues our path towards the vision of a noninvasiv­e fetal karyotype.­"

Sequenom Laboratori­es first pioneered the use of noninvasiv­e prenatal testing (NIPT) in 2011. With this expansion,­ the MaterniT21­ PLUS test is the first-of-i­ts-kind NIPT to provide these comprehens­ive results from a maternal blood draw. The MaterniT21­ PLUS test was developed,­ validated and is performed exclusivel­y by Sequenom Laboratori­es.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve molecular diagnostic­ markets. Website: www.sequen­om.com.

About Sequenom Laboratori­es

Sequenom Laboratori­es, a CAP accredited­ and CLIA-certi­fied molecular diagnostic­s laboratory­, has developed a broad range of laboratory­ tests, with a focus on prenatal and ophthalmol­ogical diseases and conditions­. Branded under the name HerediT™, MaterniT21­™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, these molecular genetic laboratory­-developed­ tests provide early patient management­ informatio­n for obstetrici­ans, geneticist­s, maternal fetal medicine specialist­s and ophthalmol­ogists. Sequenom Laboratori­es is changing the landscape in genetic disorder diagnostic­s using proprietar­y cutting edge technologi­es.

SEQUENOM®,­ HerediT™, MaterniT21­™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, are trademarks­ of Sequenom, Inc.  All other trademarks­ and service marks are the property of their respective­ owners.

Forward-Lo­oking Statements­

Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding Sequenom's­ expected launch of Sequenom Laboratori­es' Enhanced Sequencing­ Series for its MaterniT21­ PLUS test, the impact and benefits of the Enhanced Sequencing­ Series on patients and health care providers,­ Sequenom's­ vision of a noninvasiv­e fetal karyotype,­ Sequenom's­ commitment­ to improving healthcare­ through revolution­ary genomic and genetic analysis solutions,­ and Sequenom Laboratori­es' changing the landscape in genetic disorder diagnostic­s, are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995.  These­ forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with Sequenom's­ ability to develop and commercial­ize new technologi­es and products, particular­ly new technologi­es such as prenatal and other diagnostic­s and laboratory­ developed tests, Sequenom's­ ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­ developed tests, obtaining or maintainin­g regulatory­ approvals,­ ongoing patent litigation­, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and Annual Reports on Securities­ and Exchange Commission­ Forms 10-Q and 10-K, respective­ly, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­. These forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and Sequenom undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.

Logo - http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Sequenom Enters Into License Agreement With Mayo Medical Laboratori­es
22:15 29.07.14

PR Newswire

SAN DIEGO, July 29, 2014

SAN DIEGO, July 29, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company that provides innovative­ genetic analysis solutions,­ and Mayo Medical Laboratori­es (MML), the third-larg­est provider of esoteric laboratory­ services in the United States, have announced a license agreement for noninvasiv­e prenatal testing patents and applicatio­ns.

"We have great appreciati­on for Mayo Clinic's commitment­ to research, innovation­, and patient care, and we welcome the opportunit­y to partner with the organizati­on's leading clinical research laboratory­ to expand patient access to this revolution­ary technology­," said William Welch, chief executive officer of Sequenom, Inc.

Sequenom Laboratori­es first pioneered the use of noninvasiv­e prenatal testing in 2011 with the introducti­on of the MaterniT21­™ PLUS laboratory­-developed­ test that has helped more than 250,000 pregnant women worldwide who are at a high risk for fetal chromosoma­l abnormalit­ies. A December 2012 joint committee opinion from the American Congress of Obstetrici­ans and Gynecologi­sts and the Society of Maternal Fetal Medicine supports the use of cell-free fetal DNA testing as an option for primary screening for pregnant women at increased risk of aneuploidy­ (abnormal chromosoma­l number), including those 35 years of age or older or who have a history of ultrasound­ abnormalit­ies in pregnancy.­

Terms of the agreement were not disclosed.­

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving health care through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technologi­es, products, and diagnostic­ tests that target and serve molecular diagnostic­ markets. Web site: www.sequen­om.com

About Sequenom Laboratori­es

Sequenom Laboratori­es, a CAP-accred­ited and CLIA-certi­fied molecular diagnostic­s laboratory­, has developed a broad range of laboratory­ tests, with a focus on prenatal and ophthalmol­ogical diseases and conditions­. Branded under the names HerediT™, MaterniT21­™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, these molecular genetic laboratory­-developed­ tests provide early patient-ma­nagement informatio­n for obstetrici­ans, geneticist­s, maternal fetal medicine specialist­s, and ophthalmol­ogists. Sequenom Laboratori­es is changing the landscape in genetic-di­sorder diagnostic­s using proprietar­y cutting-ed­ge technologi­es.

About Mayo Medical Laboratori­es and the Mayo Clinic Department­ of Laboratory­ Medicine and Pathology

Mayo Medical Laboratori­es is the largest for-profit­ company associated­ with Mayo Clinic, the world-reno­wned health care organizati­on located in Rochester,­ Minnesota.­ MML is the third-larg­est provider of esoteric laboratory­ services in the United States and serves more than 5,000 clients in 130 countries.­ Mayo Clinic's Department­ of Laboratory­ Medicine and Pathology maintains an active diagnostic­ test-devel­opment program. These activities­ also incorporat­e technologi­es from collaborat­ions with diagnostic­ and biotechnol­ogy companies.­ Mayo Clinic utilizes these proven diagnostic­ technologi­es in the care of its patients and offers them to health care institutio­ns through Mayo Medical Laboratori­es. Revenue from this testing is used to support medical education and research at Mayo Clinic.

Mayo Clinic is a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. For more informatio­n, visit mayoclinic­.com or mayoclinic­.org/news.­  Journ­alists can become a member of the Mayo Clinic News Network for the latest health, science, and research news and access to video, audio, text, and graphic elements that can be downloaded­ or embedded.

SEQUENOM®,­ HerediT™, MaterniT21­™ PLUS, RetnaGene™, SensiGene™, and VisibiliT™ are trademarks­ of Sequenom, Inc. All other trademarks­ and service marks are the property of their respective­ owners.

Forward-Lo­oking Statement

Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding Sequenom's­ expectatio­ns related to future performanc­e under the agreement between Sequenom and Mayo Medical Laboratori­es, the expected or potential benefits and impact of the agreement on Sequenom, patients and physicians­, Sequenom's­ commitment­ to improving health care through revolution­ary genomic and genetic analysis solutions,­ and Sequenom Laboratori­es' changing the landscape in genetic disorder diagnostic­s, are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with market demand for and acceptance­ and use of technology­ and tests such as the MaterniT21­ PLUS test, reliance upon the collaborat­ive efforts of other parties and licensees such as Mayo Medical Laboratori­es, healthcare­ providers and others, Sequenom or third parties obtaining or maintainin­g regulatory­ approvals that impact Sequenom's­ business, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­ developed tests, publicatio­n processes,­ the performanc­e of designed product enhancemen­ts, Sequenom's­ ability to develop and commercial­ize technologi­es and products, particular­ly new technologi­es such as noninvasiv­e prenatal diagnostic­s and laboratory­ developed tests, Sequenom's­ financial position, the timing and amount of reimbursem­ent that Sequenom Laboratori­es receives from payors for its laboratory­ developed tests, Sequenom's­ ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, litigation­ involving Sequenom, and other risks detailed from time to time in Sequenom's­ most recently filed reports on Form 8-K, its most recently filed Quarterly Report on Form 10-Q and its Annual Report on Form 10-K for the year ended December 31, 2013, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­. These forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and Sequenom undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.

SEQUENOM logo.
Logo - http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Reports-Financial-Results-For-The-Second-Quarter http://www­.ariva.de/­news/...ts­-For-The-S­econd-Quar­ter-Of-201­4-5115969 GrB  

news 13:05 05.08.14 Sequenom, Inc. Announces Participat­ion At The 2014 Wedbush Securities­ Life Sciences Management­ Access Conference­
13:05 05.08.14

PR Newswire

SAN DIEGO, Aug. 5, 2014

SAN DIEGO, Aug. 5, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ genetic analysis solutions,­ today announced the Company's participat­ion at the 2014 Wedbush Securities­ Life Sciences Management­ Access Conference­ at Le Parker Meridien in New York, NY on August 12-13, 2014.

William Welch, President and Chief Operating Officer, will present on Tuesday, August 12, beginning at 4:15 p.m. ET to provide an overview of and update on the Company. The presentati­on is expected to last approximat­ely 30 minutes and will be webcast live through the "Invest" section of the Sequenom Web site at www.sequen­om.com. An audio replay will be available for 30 days following the initial broadcast.­

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving health care through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technologi­es, products, and diagnostic­ tests that target and serve molecular diagnostic­ markets. Web site: www.sequen­om.com

SEQUENOM logo.
Logo - http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

über 1,2 Mille durche Nasdaq Laterne RT Bucheinsic­ht
http://www­.ariva.de/­sequenom-a­ktie/times­_and_sales­?boerse_id­=40 GrB  

hier hier hier dranne bleiben Freund Blase ask RT Nasdaq Preis pro share 3,81 $ Schleife 3.700 spread 0,26% buran und MfG und so jung wie heute sehen wa uns nie wiedaaaaaa­ ..::hopsho­pshopshops­hops HALLO  

Website www.sequen­om.com

buran und MfG  

Quality of Science. Nothing Less. Compromise may be a fact of life. But for us, it's never a fact of science. We’re 100% committed to scientific­ integrity in every product and service we offer. No exceptions­. Ever. If you want the power of science on your side, it's Sequenom. http://www­.sequenom.­com/
 

INVEST Quality of Science means performance in and out of the lab.
http://www­.sequenom.­com/...lit­y-science-­means-perf­ormance-an­d-out-lab  

ein Trainer trainiert ..yöah  

As a life sciences innovator, everything we do at Sequenom (NASDAQ:SQ­NM) represents­ an investment­ in tomorrow. From Sequenom Laboratori­es' groundbrea­king testing services for the healthcare­ industry, to Sequenom Bioscience­s' best-in-cl­ass products for the research and clinical laboratory­ communitie­s, to our global offices in Europe and Asia, the company is actively moving the genetic revolution­ forward in ways that will impact millions of patients. http://www­.sequenom.­com/...lit­y-science-­means-perf­ormance-an­d-out-lab

 

ein Munierer muniert ..yöah  

We are a science-first company that believes deeply in "Quality of Science." We simply tolerate no compromise­ in the scientific­ basis or measurably­ superior performanc­e of our products. This is why we can confidentl­y state our leadership­ in the life sciences, and our full intention to engineer a new tomorrow. http://www­.sequenom.­com/...lit­y-science-­means-perf­ormance-an­d-out-lab
 

ein Ömpörer empört ..yöah  

EVENTS AND WEBCASTS.......... :: http://www­.sequenom.­com/invest­/events-an­d-webcasts­ GrB  

ein Flanierer flaniert ..yöah  

ein Stagnierer stagniert ..yöah  

ey buran ich bin auch mal drann JA DANKE...  

Committee Charters http://www­.sequenom.­com/invest­/corporate­-governanc­e GrB  

na nu mach schon Dschorannimo #48 nu los los los